PHARMACIE BALDY MEJEAN CRETAL is a French company
founded 20 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in CARCASSONNE (11000),
this company of category PME
shows in 2023 a revenue of 19.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE BALDY MEJEAN CRETAL (SIREN 483309126)
Indicator
2024
2023
2022
2021
2020
2019
2018
2016
Revenue
N/C
19 172 192 €
16 547 413 €
17 806 443 €
N/C
16 451 643 €
16 554 149 €
12 117 849 €
Net income
448 481 €
265 964 €
177 788 €
802 951 €
873 761 €
689 775 €
696 838 €
376 032 €
EBITDA
N/C
489 482 €
364 615 €
1 190 395 €
N/C
1 057 951 €
959 688 €
585 988 €
Net margin
N/C
1.4%
1.1%
4.5%
N/C
4.2%
4.2%
3.1%
Revenue and income statement
In 2024, PHARMACIE BALDY MEJEAN CRETAL generates positive net income of 448 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 376 k€ -> 448 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
448 481 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 11%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 57%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
11.263%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
56.603%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2018
2019
2020
2021
2022
2023
2024
Debt ratio
48.596
24.527
18.913
5.974
5.699
4.569
12.102
11.263
Financial autonomy
40.153
51.427
56.775
61.121
64.128
57.034
53.963
56.603
Repayment capacity
2.309
1.016
0.827
None
0.306
0.77
1.401
None
Cash flow / Revenue
3.555%
4.402%
4.577%
None%
5.002%
1.535%
2.014%
None%
Sector positioning
Debt ratio
11.262024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Excellent
In 2024, the debt ratio of PHARMACIE BALDY MEJEAN CR... (11.26) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
56.6%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good
In 2024, the financial autonomy of PHARMACIE BALDY MEJEAN CR... (56.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
1.4 years2023
2022
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Good
In 2023, the repayment capacity of PHARMACIE BALDY MEJEAN CR... (1.40) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 162.65. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
105.403
145.826
164.913
166.136
182.338
143.115
152.929
162.645
Interest coverage
5.836
1.52
1.277
None
0.414
0.769
0.553
None
Sector positioning
Liquidity ratio
162.652024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Average+16 pts over 3 years
In 2024, the liquidity ratio of PHARMACIE BALDY MEJEAN CR... (162.65) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
0.55x2023
2022
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of PHARMACIE BALDY MEJEAN CR... (0.6x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE BALDY MEJEAN CRETAL
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2018
2019
2020
2021
2022
2023
2024
Operating WCR
1 853 910 €
2 753 121 €
2 880 518 €
0 €
3 212 995 €
3 325 203 €
3 704 451 €
0 €
Inventory turnover (days)
49
45
51
0
49
61
56
0
Customer payment term (days)
5
6
8
0
6
9
13
0
Supplier payment term (days)
63
51
47
0
47
56
51
0
Positioning of PHARMACIE BALDY MEJEAN CRETAL in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE BALDY MEJEAN CRETAL is estimated at
6 261 126 €
(range 4 360 149€ - 9 367 003€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
4360k€6261k€9367k€
6 261 126 €Range: 4 360 149€ - 9 367 003€
NAF 5 année 2024
Valuation method used
Net Income Multiple
448 481 €
×
14.0x
=6 261 126 €
Range: 4 360 149€ - 9 367 003€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE BALDY MEJEAN CRETAL with other companies in the same sector:
Frequently asked questions about PHARMACIE BALDY MEJEAN CRETAL
What is the revenue of PHARMACIE BALDY MEJEAN CRETAL ?
The revenue of PHARMACIE BALDY MEJEAN CRETAL in 2023 is 19.2 M€.
Is PHARMACIE BALDY MEJEAN CRETAL profitable?
Yes, PHARMACIE BALDY MEJEAN CRETAL generated a net profit of 448 k€ in 2024.
Where is the headquarters of PHARMACIE BALDY MEJEAN CRETAL ?
The headquarters of PHARMACIE BALDY MEJEAN CRETAL is located in CARCASSONNE (11000), in the department Aude.
Where to find the tax return of PHARMACIE BALDY MEJEAN CRETAL ?
The tax return of PHARMACIE BALDY MEJEAN CRETAL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE BALDY MEJEAN CRETAL operate?
PHARMACIE BALDY MEJEAN CRETAL operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart